nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Raloxifene—osteoporosis	0.0723	0.149	CbGbCtD
Trametinib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0699	0.144	CbGbCtD
Trametinib—CYP2C8—Cholecalciferol—osteoporosis	0.0558	0.115	CbGbCtD
Trametinib—CYP2C8—Estradiol—osteoporosis	0.045	0.0927	CbGbCtD
Trametinib—CYP3A4—Estropipate—osteoporosis	0.044	0.0906	CbGbCtD
Trametinib—CYP3A4—Calcitriol—osteoporosis	0.044	0.0906	CbGbCtD
Trametinib—CYP3A4—Ergocalciferol—osteoporosis	0.0351	0.0724	CbGbCtD
Trametinib—CYP3A4—Raloxifene—osteoporosis	0.0293	0.0604	CbGbCtD
Trametinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0283	0.0584	CbGbCtD
Trametinib—CYP3A4—Cholecalciferol—osteoporosis	0.0226	0.0467	CbGbCtD
Trametinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0208	0.0428	CbGbCtD
Trametinib—CYP3A4—Estradiol—osteoporosis	0.0183	0.0376	CbGbCtD
Trametinib—Gastrointestinal pain—Estropipate—osteoporosis	0.000279	0.001	CcSEcCtD
Trametinib—Decreased appetite—Calcitriol—osteoporosis	0.000279	0.000998	CcSEcCtD
Trametinib—Mental disorder—Conjugated Estrogens—osteoporosis	0.000278	0.000996	CcSEcCtD
Trametinib—Back pain—Zoledronate—osteoporosis	0.000278	0.000995	CcSEcCtD
Trametinib—Oedema—Ethinyl Estradiol—osteoporosis	0.000277	0.000991	CcSEcCtD
Trametinib—Malnutrition—Conjugated Estrogens—osteoporosis	0.000276	0.00099	CcSEcCtD
Trametinib—Erythema—Conjugated Estrogens—osteoporosis	0.000276	0.00099	CcSEcCtD
Trametinib—Muscle spasms—Zoledronate—osteoporosis	0.000276	0.000988	CcSEcCtD
Trametinib—Dry mouth—Risedronate—osteoporosis	0.000275	0.000986	CcSEcCtD
Trametinib—Urinary tract infection—Estradiol—osteoporosis	0.000275	0.000986	CcSEcCtD
Trametinib—Gastrointestinal pain—Alendronate—osteoporosis	0.000275	0.000985	CcSEcCtD
Trametinib—Infection—Ethinyl Estradiol—osteoporosis	0.000275	0.000985	CcSEcCtD
Trametinib—Cough—Pamidronate—osteoporosis	0.000274	0.000982	CcSEcCtD
Trametinib—Constipation—Calcitriol—osteoporosis	0.000274	0.000982	CcSEcCtD
Trametinib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000271	0.000972	CcSEcCtD
Trametinib—Hypertension—Pamidronate—osteoporosis	0.000271	0.000972	CcSEcCtD
Trametinib—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000271	0.000969	CcSEcCtD
Trametinib—Vision blurred—Zoledronate—osteoporosis	0.000271	0.000969	CcSEcCtD
Trametinib—Gastrointestinal pain—Raloxifene—osteoporosis	0.00027	0.000969	CcSEcCtD
Trametinib—Diarrhoea—Etidronic acid—osteoporosis	0.00027	0.000967	CcSEcCtD
Trametinib—Haematuria—Estradiol—osteoporosis	0.00027	0.000967	CcSEcCtD
Trametinib—Body temperature increased—Estropipate—osteoporosis	0.00027	0.000967	CcSEcCtD
Trametinib—Abdominal pain—Estropipate—osteoporosis	0.00027	0.000967	CcSEcCtD
Trametinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000269	0.000963	CcSEcCtD
Trametinib—Infection—Risedronate—osteoporosis	0.000268	0.00096	CcSEcCtD
Trametinib—Gastrointestinal pain—Ibandronate—osteoporosis	0.000268	0.000959	CcSEcCtD
Trametinib—Arthralgia—Pamidronate—osteoporosis	0.000268	0.000958	CcSEcCtD
Trametinib—Myalgia—Pamidronate—osteoporosis	0.000268	0.000958	CcSEcCtD
Trametinib—Back pain—Conjugated Estrogens—osteoporosis	0.000267	0.000958	CcSEcCtD
Trametinib—Epistaxis—Estradiol—osteoporosis	0.000267	0.000956	CcSEcCtD
Trametinib—Abdominal pain—Alendronate—osteoporosis	0.000266	0.000952	CcSEcCtD
Trametinib—Body temperature increased—Alendronate—osteoporosis	0.000266	0.000952	CcSEcCtD
Trametinib—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000266	0.000952	CcSEcCtD
Trametinib—Anaemia—Zoledronate—osteoporosis	0.000265	0.00095	CcSEcCtD
Trametinib—Nervous system disorder—Risedronate—osteoporosis	0.000265	0.000948	CcSEcCtD
Trametinib—Skin disorder—Risedronate—osteoporosis	0.000262	0.000939	CcSEcCtD
Trametinib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000262	0.000939	CcSEcCtD
Trametinib—Abdominal pain—Raloxifene—osteoporosis	0.000261	0.000936	CcSEcCtD
Trametinib—Body temperature increased—Raloxifene—osteoporosis	0.000261	0.000936	CcSEcCtD
Trametinib—Vision blurred—Conjugated Estrogens—osteoporosis	0.00026	0.000933	CcSEcCtD
Trametinib—Abdominal pain—Ibandronate—osteoporosis	0.000259	0.000927	CcSEcCtD
Trametinib—Body temperature increased—Ibandronate—osteoporosis	0.000259	0.000927	CcSEcCtD
Trametinib—Leukopenia—Zoledronate—osteoporosis	0.000257	0.00092	CcSEcCtD
Trametinib—Oedema—Pamidronate—osteoporosis	0.000256	0.000919	CcSEcCtD
Trametinib—Haemoglobin—Estradiol—osteoporosis	0.000255	0.000915	CcSEcCtD
Trametinib—Infection—Pamidronate—osteoporosis	0.000255	0.000913	CcSEcCtD
Trametinib—Haemorrhage—Estradiol—osteoporosis	0.000254	0.00091	CcSEcCtD
Trametinib—Abdominal pain—Calcitriol—osteoporosis	0.000253	0.000907	CcSEcCtD
Trametinib—Body temperature increased—Calcitriol—osteoporosis	0.000253	0.000907	CcSEcCtD
Trametinib—Nervous system disorder—Pamidronate—osteoporosis	0.000252	0.000901	CcSEcCtD
Trametinib—Thrombocytopenia—Pamidronate—osteoporosis	0.000251	0.000899	CcSEcCtD
Trametinib—Urinary tract disorder—Estradiol—osteoporosis	0.000251	0.000899	CcSEcCtD
Trametinib—Vomiting—Etidronic acid—osteoporosis	0.000251	0.000899	CcSEcCtD
Trametinib—Cough—Zoledronate—osteoporosis	0.00025	0.000897	CcSEcCtD
Trametinib—Oedema peripheral—Estradiol—osteoporosis	0.00025	0.000897	CcSEcCtD
Trametinib—Connective tissue disorder—Estradiol—osteoporosis	0.00025	0.000894	CcSEcCtD
Trametinib—Urethral disorder—Estradiol—osteoporosis	0.000249	0.000892	CcSEcCtD
Trametinib—Rash—Etidronic acid—osteoporosis	0.000249	0.000891	CcSEcCtD
Trametinib—Dermatitis—Etidronic acid—osteoporosis	0.000249	0.00089	CcSEcCtD
Trametinib—Hyperhidrosis—Pamidronate—osteoporosis	0.000248	0.000888	CcSEcCtD
Trametinib—Hypertension—Zoledronate—osteoporosis	0.000248	0.000888	CcSEcCtD
Trametinib—Headache—Etidronic acid—osteoporosis	0.000247	0.000885	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000246	0.00088	CcSEcCtD
Trametinib—Asthenia—Estropipate—osteoporosis	0.000245	0.000877	CcSEcCtD
Trametinib—Myalgia—Zoledronate—osteoporosis	0.000244	0.000875	CcSEcCtD
Trametinib—Arthralgia—Zoledronate—osteoporosis	0.000244	0.000875	CcSEcCtD
Trametinib—Insomnia—Risedronate—osteoporosis	0.000244	0.000874	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000243	0.000869	CcSEcCtD
Trametinib—Pruritus—Estropipate—osteoporosis	0.000242	0.000865	CcSEcCtD
Trametinib—Asthenia—Alendronate—osteoporosis	0.000241	0.000864	CcSEcCtD
Trametinib—Cough—Conjugated Estrogens—osteoporosis	0.000241	0.000864	CcSEcCtD
Trametinib—Dry mouth—Zoledronate—osteoporosis	0.000239	0.000856	CcSEcCtD
Trametinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000239	0.000856	CcSEcCtD
Trametinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000239	0.000855	CcSEcCtD
Trametinib—Pruritus—Alendronate—osteoporosis	0.000238	0.000852	CcSEcCtD
Trametinib—Eye disorder—Estradiol—osteoporosis	0.000237	0.000851	CcSEcCtD
Trametinib—Constipation—Ethinyl Estradiol—osteoporosis	0.000237	0.000848	CcSEcCtD
Trametinib—Cardiac disorder—Estradiol—osteoporosis	0.000236	0.000845	CcSEcCtD
Trametinib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000235	0.000843	CcSEcCtD
Trametinib—Myalgia—Conjugated Estrogens—osteoporosis	0.000235	0.000843	CcSEcCtD
Trametinib—Asthenia—Ibandronate—osteoporosis	0.000235	0.000841	CcSEcCtD
Trametinib—Nausea—Etidronic acid—osteoporosis	0.000234	0.00084	CcSEcCtD
Trametinib—Oedema—Zoledronate—osteoporosis	0.000234	0.000839	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000234	0.000837	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000234	0.000837	CcSEcCtD
Trametinib—Diarrhoea—Estropipate—osteoporosis	0.000234	0.000837	CcSEcCtD
Trametinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000233	0.000834	CcSEcCtD
Trametinib—Infection—Zoledronate—osteoporosis	0.000233	0.000834	CcSEcCtD
Trametinib—Fatigue—Risedronate—osteoporosis	0.000233	0.000833	CcSEcCtD
Trametinib—Insomnia—Pamidronate—osteoporosis	0.000232	0.000831	CcSEcCtD
Trametinib—Pruritus—Ibandronate—osteoporosis	0.000232	0.00083	CcSEcCtD
Trametinib—Constipation—Risedronate—osteoporosis	0.000231	0.000826	CcSEcCtD
Trametinib—Angiopathy—Estradiol—osteoporosis	0.000231	0.000826	CcSEcCtD
Trametinib—Diarrhoea—Alendronate—osteoporosis	0.00023	0.000824	CcSEcCtD
Trametinib—Asthenia—Calcitriol—osteoporosis	0.00023	0.000824	CcSEcCtD
Trametinib—Nervous system disorder—Zoledronate—osteoporosis	0.00023	0.000823	CcSEcCtD
Trametinib—Thrombocytopenia—Zoledronate—osteoporosis	0.000229	0.000822	CcSEcCtD
Trametinib—Mediastinal disorder—Estradiol—osteoporosis	0.000229	0.00082	CcSEcCtD
Trametinib—Chills—Estradiol—osteoporosis	0.000228	0.000817	CcSEcCtD
Trametinib—Skin disorder—Zoledronate—osteoporosis	0.000228	0.000815	CcSEcCtD
Trametinib—Pruritus—Calcitriol—osteoporosis	0.000227	0.000812	CcSEcCtD
Trametinib—Hyperhidrosis—Zoledronate—osteoporosis	0.000226	0.000811	CcSEcCtD
Trametinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000226	0.00081	CcSEcCtD
Trametinib—Diarrhoea—Raloxifene—osteoporosis	0.000226	0.00081	CcSEcCtD
Trametinib—Dizziness—Estropipate—osteoporosis	0.000226	0.000809	CcSEcCtD
Trametinib—Oedema—Conjugated Estrogens—osteoporosis	0.000226	0.000808	CcSEcCtD
Trametinib—Infection—Conjugated Estrogens—osteoporosis	0.000224	0.000803	CcSEcCtD
Trametinib—Diarrhoea—Ibandronate—osteoporosis	0.000224	0.000802	CcSEcCtD
Trametinib—Decreased appetite—Pamidronate—osteoporosis	0.000223	0.000799	CcSEcCtD
Trametinib—Mental disorder—Estradiol—osteoporosis	0.000223	0.000797	CcSEcCtD
Trametinib—Dizziness—Alendronate—osteoporosis	0.000222	0.000796	CcSEcCtD
Trametinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000221	0.000793	CcSEcCtD
Trametinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000221	0.000792	CcSEcCtD
Trametinib—Malnutrition—Estradiol—osteoporosis	0.000221	0.000792	CcSEcCtD
Trametinib—Erythema—Estradiol—osteoporosis	0.000221	0.000792	CcSEcCtD
Trametinib—Fatigue—Pamidronate—osteoporosis	0.000221	0.000792	CcSEcCtD
Trametinib—Gastrointestinal pain—Risedronate—osteoporosis	0.000221	0.00079	CcSEcCtD
Trametinib—Constipation—Pamidronate—osteoporosis	0.000219	0.000786	CcSEcCtD
Trametinib—Diarrhoea—Calcitriol—osteoporosis	0.000219	0.000785	CcSEcCtD
Trametinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000219	0.000785	CcSEcCtD
Trametinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000219	0.000784	CcSEcCtD
Trametinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000219	0.000784	CcSEcCtD
Trametinib—Dizziness—Raloxifene—osteoporosis	0.000219	0.000783	CcSEcCtD
Trametinib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000218	0.000781	CcSEcCtD
Trametinib—Vomiting—Estropipate—osteoporosis	0.000217	0.000777	CcSEcCtD
Trametinib—Dysgeusia—Estradiol—osteoporosis	0.000217	0.000776	CcSEcCtD
Trametinib—Dizziness—Ibandronate—osteoporosis	0.000216	0.000775	CcSEcCtD
Trametinib—Rash—Estropipate—osteoporosis	0.000215	0.000771	CcSEcCtD
Trametinib—Dermatitis—Estropipate—osteoporosis	0.000215	0.00077	CcSEcCtD
Trametinib—Back pain—Estradiol—osteoporosis	0.000214	0.000766	CcSEcCtD
Trametinib—Headache—Estropipate—osteoporosis	0.000214	0.000766	CcSEcCtD
Trametinib—Vomiting—Alendronate—osteoporosis	0.000214	0.000766	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000213	0.000764	CcSEcCtD
Trametinib—Abdominal pain—Risedronate—osteoporosis	0.000213	0.000764	CcSEcCtD
Trametinib—Body temperature increased—Risedronate—osteoporosis	0.000213	0.000764	CcSEcCtD
Trametinib—Muscle spasms—Estradiol—osteoporosis	0.000213	0.000762	CcSEcCtD
Trametinib—Rash—Alendronate—osteoporosis	0.000212	0.000759	CcSEcCtD
Trametinib—Insomnia—Zoledronate—osteoporosis	0.000212	0.000759	CcSEcCtD
Trametinib—Dermatitis—Alendronate—osteoporosis	0.000212	0.000759	CcSEcCtD
Trametinib—Headache—Alendronate—osteoporosis	0.000211	0.000754	CcSEcCtD
Trametinib—Vomiting—Raloxifene—osteoporosis	0.00021	0.000753	CcSEcCtD
Trametinib—Gastrointestinal pain—Pamidronate—osteoporosis	0.00021	0.000751	CcSEcCtD
Trametinib—Rash—Raloxifene—osteoporosis	0.000208	0.000747	CcSEcCtD
Trametinib—Dermatitis—Raloxifene—osteoporosis	0.000208	0.000746	CcSEcCtD
Trametinib—Vomiting—Ibandronate—osteoporosis	0.000208	0.000746	CcSEcCtD
Trametinib—Headache—Raloxifene—osteoporosis	0.000207	0.000742	CcSEcCtD
Trametinib—Rash—Ibandronate—osteoporosis	0.000206	0.000739	CcSEcCtD
Trametinib—Dermatitis—Ibandronate—osteoporosis	0.000206	0.000739	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000206	0.000736	CcSEcCtD
Trametinib—Headache—Ibandronate—osteoporosis	0.000205	0.000735	CcSEcCtD
Trametinib—Insomnia—Conjugated Estrogens—osteoporosis	0.000204	0.000731	CcSEcCtD
Trametinib—Vomiting—Calcitriol—osteoporosis	0.000204	0.00073	CcSEcCtD
Trametinib—Decreased appetite—Zoledronate—osteoporosis	0.000204	0.000729	CcSEcCtD
Trametinib—Nausea—Estropipate—osteoporosis	0.000203	0.000726	CcSEcCtD
Trametinib—Abdominal pain—Pamidronate—osteoporosis	0.000203	0.000726	CcSEcCtD
Trametinib—Body temperature increased—Pamidronate—osteoporosis	0.000203	0.000726	CcSEcCtD
Trametinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000202	0.000724	CcSEcCtD
Trametinib—Rash—Calcitriol—osteoporosis	0.000202	0.000724	CcSEcCtD
Trametinib—Fatigue—Zoledronate—osteoporosis	0.000202	0.000723	CcSEcCtD
Trametinib—Dermatitis—Calcitriol—osteoporosis	0.000202	0.000723	CcSEcCtD
Trametinib—Headache—Calcitriol—osteoporosis	0.000201	0.000719	CcSEcCtD
Trametinib—Constipation—Zoledronate—osteoporosis	0.0002	0.000718	CcSEcCtD
Trametinib—Nausea—Alendronate—osteoporosis	0.0002	0.000715	CcSEcCtD
Trametinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000199	0.000711	CcSEcCtD
Trametinib—Nausea—Raloxifene—osteoporosis	0.000196	0.000704	CcSEcCtD
Trametinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000196	0.000702	CcSEcCtD
Trametinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000196	0.000701	CcSEcCtD
Trametinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000195	0.000698	CcSEcCtD
Trametinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000194	0.000697	CcSEcCtD
Trametinib—Nausea—Ibandronate—osteoporosis	0.000194	0.000696	CcSEcCtD
Trametinib—Asthenia—Risedronate—osteoporosis	0.000194	0.000693	CcSEcCtD
Trametinib—Cough—Estradiol—osteoporosis	0.000193	0.000691	CcSEcCtD
Trametinib—Constipation—Conjugated Estrogens—osteoporosis	0.000193	0.000691	CcSEcCtD
Trametinib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000192	0.000686	CcSEcCtD
Trametinib—Hypertension—Estradiol—osteoporosis	0.000191	0.000684	CcSEcCtD
Trametinib—Pruritus—Risedronate—osteoporosis	0.000191	0.000684	CcSEcCtD
Trametinib—Nausea—Calcitriol—osteoporosis	0.00019	0.000682	CcSEcCtD
Trametinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000189	0.000678	CcSEcCtD
Trametinib—Myalgia—Estradiol—osteoporosis	0.000188	0.000675	CcSEcCtD
Trametinib—Arthralgia—Estradiol—osteoporosis	0.000188	0.000675	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000187	0.00067	CcSEcCtD
Trametinib—Abdominal pain—Zoledronate—osteoporosis	0.000185	0.000663	CcSEcCtD
Trametinib—Body temperature increased—Zoledronate—osteoporosis	0.000185	0.000663	CcSEcCtD
Trametinib—Diarrhoea—Risedronate—osteoporosis	0.000185	0.000661	CcSEcCtD
Trametinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000184	0.000661	CcSEcCtD
Trametinib—Dry mouth—Estradiol—osteoporosis	0.000184	0.00066	CcSEcCtD
Trametinib—Asthenia—Pamidronate—osteoporosis	0.000184	0.000659	CcSEcCtD
Trametinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000183	0.000655	CcSEcCtD
Trametinib—Pruritus—Pamidronate—osteoporosis	0.000181	0.00065	CcSEcCtD
Trametinib—Oedema—Estradiol—osteoporosis	0.000181	0.000647	CcSEcCtD
Trametinib—Infection—Estradiol—osteoporosis	0.000179	0.000642	CcSEcCtD
Trametinib—Dizziness—Risedronate—osteoporosis	0.000178	0.000639	CcSEcCtD
Trametinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000178	0.000639	CcSEcCtD
Trametinib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000178	0.000639	CcSEcCtD
Trametinib—Nervous system disorder—Estradiol—osteoporosis	0.000177	0.000634	CcSEcCtD
Trametinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000176	0.00063	CcSEcCtD
Trametinib—Diarrhoea—Pamidronate—osteoporosis	0.000175	0.000629	CcSEcCtD
Trametinib—Skin disorder—Estradiol—osteoporosis	0.000175	0.000628	CcSEcCtD
Trametinib—Hyperhidrosis—Estradiol—osteoporosis	0.000175	0.000625	CcSEcCtD
Trametinib—Rash—Ethinyl Estradiol—osteoporosis	0.000174	0.000625	CcSEcCtD
Trametinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000174	0.000624	CcSEcCtD
Trametinib—Headache—Ethinyl Estradiol—osteoporosis	0.000173	0.000621	CcSEcCtD
Trametinib—Vomiting—Risedronate—osteoporosis	0.000172	0.000614	CcSEcCtD
Trametinib—Rash—Risedronate—osteoporosis	0.00017	0.000609	CcSEcCtD
Trametinib—Dermatitis—Risedronate—osteoporosis	0.00017	0.000609	CcSEcCtD
Trametinib—Dizziness—Pamidronate—osteoporosis	0.00017	0.000607	CcSEcCtD
Trametinib—Headache—Risedronate—osteoporosis	0.000169	0.000605	CcSEcCtD
Trametinib—Asthenia—Zoledronate—osteoporosis	0.000168	0.000602	CcSEcCtD
Trametinib—Pruritus—Zoledronate—osteoporosis	0.000166	0.000594	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000164	0.000589	CcSEcCtD
Trametinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000164	0.000589	CcSEcCtD
Trametinib—Insomnia—Estradiol—osteoporosis	0.000163	0.000585	CcSEcCtD
Trametinib—Vomiting—Pamidronate—osteoporosis	0.000163	0.000584	CcSEcCtD
Trametinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000162	0.00058	CcSEcCtD
Trametinib—Rash—Pamidronate—osteoporosis	0.000162	0.000579	CcSEcCtD
Trametinib—Dermatitis—Pamidronate—osteoporosis	0.000162	0.000579	CcSEcCtD
Trametinib—Headache—Pamidronate—osteoporosis	0.000161	0.000575	CcSEcCtD
Trametinib—Diarrhoea—Zoledronate—osteoporosis	0.00016	0.000574	CcSEcCtD
Trametinib—Nausea—Risedronate—osteoporosis	0.00016	0.000574	CcSEcCtD
Trametinib—Pruritus—Conjugated Estrogens—osteoporosis	0.00016	0.000572	CcSEcCtD
Trametinib—Decreased appetite—Estradiol—osteoporosis	0.000157	0.000562	CcSEcCtD
Trametinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000156	0.000558	CcSEcCtD
Trametinib—Fatigue—Estradiol—osteoporosis	0.000156	0.000558	CcSEcCtD
Trametinib—Dizziness—Zoledronate—osteoporosis	0.000155	0.000555	CcSEcCtD
Trametinib—Constipation—Estradiol—osteoporosis	0.000154	0.000553	CcSEcCtD
Trametinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000154	0.000553	CcSEcCtD
Trametinib—Nausea—Pamidronate—osteoporosis	0.000152	0.000546	CcSEcCtD
Trametinib—Dizziness—Conjugated Estrogens—osteoporosis	0.000149	0.000534	CcSEcCtD
Trametinib—Vomiting—Zoledronate—osteoporosis	0.000149	0.000534	CcSEcCtD
Trametinib—Rash—Zoledronate—osteoporosis	0.000148	0.000529	CcSEcCtD
Trametinib—Gastrointestinal pain—Estradiol—osteoporosis	0.000148	0.000529	CcSEcCtD
Trametinib—Dermatitis—Zoledronate—osteoporosis	0.000148	0.000529	CcSEcCtD
Trametinib—Headache—Zoledronate—osteoporosis	0.000147	0.000526	CcSEcCtD
Trametinib—Vomiting—Conjugated Estrogens—osteoporosis	0.000143	0.000514	CcSEcCtD
Trametinib—Abdominal pain—Estradiol—osteoporosis	0.000143	0.000511	CcSEcCtD
Trametinib—Body temperature increased—Estradiol—osteoporosis	0.000143	0.000511	CcSEcCtD
Trametinib—Rash—Conjugated Estrogens—osteoporosis	0.000142	0.000509	CcSEcCtD
Trametinib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000142	0.000509	CcSEcCtD
Trametinib—Headache—Conjugated Estrogens—osteoporosis	0.000141	0.000506	CcSEcCtD
Trametinib—Nausea—Zoledronate—osteoporosis	0.000139	0.000498	CcSEcCtD
Trametinib—Nausea—Conjugated Estrogens—osteoporosis	0.000134	0.00048	CcSEcCtD
Trametinib—Asthenia—Estradiol—osteoporosis	0.00013	0.000464	CcSEcCtD
Trametinib—Pruritus—Estradiol—osteoporosis	0.000128	0.000457	CcSEcCtD
Trametinib—Diarrhoea—Estradiol—osteoporosis	0.000124	0.000442	CcSEcCtD
Trametinib—Dizziness—Estradiol—osteoporosis	0.000119	0.000428	CcSEcCtD
Trametinib—Vomiting—Estradiol—osteoporosis	0.000115	0.000411	CcSEcCtD
Trametinib—Rash—Estradiol—osteoporosis	0.000114	0.000408	CcSEcCtD
Trametinib—Dermatitis—Estradiol—osteoporosis	0.000114	0.000407	CcSEcCtD
Trametinib—Headache—Estradiol—osteoporosis	0.000113	0.000405	CcSEcCtD
Trametinib—Nausea—Estradiol—osteoporosis	0.000107	0.000384	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—AGER—osteoporosis	5.67e-05	0.000241	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LRP5—osteoporosis	5.66e-05	0.000241	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ADCY5—osteoporosis	5.65e-05	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	5.64e-05	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Disease—P4HB—osteoporosis	5.63e-05	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—osteoporosis	5.62e-05	0.000239	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NFATC1—osteoporosis	5.61e-05	0.000238	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—IL6—osteoporosis	5.57e-05	0.000237	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—IL6—osteoporosis	5.57e-05	0.000237	CbGpPWpGaD
Trametinib—MAP2K2—Disease—DKK1—osteoporosis	5.57e-05	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—Disease—GAPDH—osteoporosis	5.53e-05	0.000235	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1B—osteoporosis	5.5e-05	0.000234	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—LEP—osteoporosis	5.48e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	5.44e-05	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	5.43e-05	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LRP6—osteoporosis	5.41e-05	0.00023	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PTHLH—osteoporosis	5.38e-05	0.000229	CbGpPWpGaD
Trametinib—MAP2K2—Disease—WNT1—osteoporosis	5.36e-05	0.000228	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—IL6—osteoporosis	5.33e-05	0.000227	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.33e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AGER—osteoporosis	5.3e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ADCY5—osteoporosis	5.28e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	5.27e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NFATC1—osteoporosis	5.25e-05	0.000223	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—IL6—osteoporosis	5.25e-05	0.000223	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FGA—osteoporosis	5.22e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—IL6—osteoporosis	5.21e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—IL6—osteoporosis	5.21e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Disease—DKK1—osteoporosis	5.21e-05	0.000221	CbGpPWpGaD
Trametinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.21e-05	0.000221	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—POMC—osteoporosis	5.15e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1B—osteoporosis	5.14e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—LEP—osteoporosis	5.12e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	5.07e-05	0.000215	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CALCA—osteoporosis	5.06e-05	0.000215	CbGpPWpGaD
Trametinib—MAP2K1—Disease—WNT1—osteoporosis	5.02e-05	0.000213	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—IL6—osteoporosis	5.01e-05	0.000213	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—IL6—osteoporosis	4.99e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—IL6—osteoporosis	4.99e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—IL6—osteoporosis	4.96e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PSMA2—osteoporosis	4.96e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PSMA5—osteoporosis	4.96e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IRS2—osteoporosis	4.94e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—IL6—osteoporosis	4.94e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—IL6—osteoporosis	4.91e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TLN1—osteoporosis	4.89e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGA—osteoporosis	4.88e-05	0.000207	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PKM—osteoporosis	4.86e-05	0.000206	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—FDPS—osteoporosis	4.86e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CALCA—osteoporosis	4.74e-05	0.000201	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—osteoporosis	4.69e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—osteoporosis	4.67e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ENO1—osteoporosis	4.65e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—osteoporosis	4.65e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—osteoporosis	4.65e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	4.65e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—osteoporosis	4.64e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PSMA2—osteoporosis	4.64e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PSMA5—osteoporosis	4.64e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IRS2—osteoporosis	4.62e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—osteoporosis	4.62e-05	0.000196	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PGLS—osteoporosis	4.61e-05	0.000196	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPD2—osteoporosis	4.61e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—osteoporosis	4.6e-05	0.000196	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	4.6e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6R—osteoporosis	4.59e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PSMA2—osteoporosis	4.58e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PSMA5—osteoporosis	4.58e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TLN1—osteoporosis	4.57e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—osteoporosis	4.56e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—osteoporosis	4.54e-05	0.000193	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	4.54e-05	0.000193	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ENO1—osteoporosis	4.35e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—osteoporosis	4.35e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—osteoporosis	4.35e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	4.35e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IRS1—osteoporosis	4.31e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—osteoporosis	4.31e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6R—osteoporosis	4.29e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PSMA2—osteoporosis	4.29e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PSMA5—osteoporosis	4.29e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CALCA—osteoporosis	4.27e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—osteoporosis	4.27e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—osteoporosis	4.25e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—P4HB—osteoporosis	4.21e-05	0.000179	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ATIC—osteoporosis	4.21e-05	0.000179	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PNP—osteoporosis	4.21e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KL—osteoporosis	4.2e-05	0.000178	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	4.12e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTH—osteoporosis	4.1e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6R—osteoporosis	4.05e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IRS1—osteoporosis	4.04e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAP1A—osteoporosis	4.03e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CALCA—osteoporosis	4e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CNR2—osteoporosis	3.99e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	3.98e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—P4HB—osteoporosis	3.94e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFATC1—osteoporosis	3.93e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KL—osteoporosis	3.93e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—DKK1—osteoporosis	3.9e-05	0.000166	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KL—osteoporosis	3.88e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	3.85e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTH—osteoporosis	3.84e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6R—osteoporosis	3.79e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAP1A—osteoporosis	3.77e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—WNT1—osteoporosis	3.76e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CNR2—osteoporosis	3.74e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	3.72e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFATC1—osteoporosis	3.68e-05	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGA—osteoporosis	3.65e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—DKK1—osteoporosis	3.65e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KL—osteoporosis	3.63e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADCY5—osteoporosis	3.6e-05	0.000153	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—OXCT1—osteoporosis	3.58e-05	0.000152	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CA2—osteoporosis	3.58e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—WNT1—osteoporosis	3.51e-05	0.000149	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MGLL—osteoporosis	3.49e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGA—osteoporosis	3.42e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTHLH—osteoporosis	3.4e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BMP2—osteoporosis	3.4e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADCY5—osteoporosis	3.37e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGB—osteoporosis	3.32e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AGER—osteoporosis	3.3e-05	0.00014	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.29e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ADCY5—osteoporosis	3.29e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—osteoporosis	3.22e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PSMA2—osteoporosis	3.21e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PSMA5—osteoporosis	3.21e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BMP2—osteoporosis	3.18e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTHLH—osteoporosis	3.18e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—osteoporosis	3.17e-05	0.000134	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGB—osteoporosis	3.11e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AGER—osteoporosis	3.09e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ADCY5—osteoporosis	3.08e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ADCY5—osteoporosis	3.04e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—osteoporosis	3.01e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PSMA2—osteoporosis	3e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PSMA5—osteoporosis	3e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CALCA—osteoporosis	2.99e-05	0.000127	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—IDH2—osteoporosis	2.97e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—osteoporosis	2.96e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IRS2—osteoporosis	2.88e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—osteoporosis	2.86e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ADCY5—osteoporosis	2.84e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CALCA—osteoporosis	2.8e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTHFR—osteoporosis	2.79e-05	0.000119	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP27A1—osteoporosis	2.79e-05	0.000119	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—POMC—osteoporosis	2.76e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KL—osteoporosis	2.72e-05	0.000115	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ACP5—osteoporosis	2.71e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—osteoporosis	2.71e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IRS2—osteoporosis	2.69e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—osteoporosis	2.68e-05	0.000114	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.68e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IRS2—osteoporosis	2.66e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—POMC—osteoporosis	2.65e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTHFR—osteoporosis	2.61e-05	0.000111	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FDPS—osteoporosis	2.61e-05	0.000111	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PKM—osteoporosis	2.61e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6R—osteoporosis	2.58e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KL—osteoporosis	2.54e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—osteoporosis	2.54e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—osteoporosis	2.53e-05	0.000108	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TPI1—osteoporosis	2.52e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IRS1—osteoporosis	2.51e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IRS2—osteoporosis	2.49e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—POMC—osteoporosis	2.48e-05	0.000105	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPD2—osteoporosis	2.47e-05	0.000105	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PGLS—osteoporosis	2.47e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6R—osteoporosis	2.42e-05	0.000103	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—P4HB—osteoporosis	2.37e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—osteoporosis	2.37e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6R—osteoporosis	2.36e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IRS1—osteoporosis	2.35e-05	9.99e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GAPDH—osteoporosis	2.33e-05	9.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IRS1—osteoporosis	2.32e-05	9.86e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RAP1A—osteoporosis	2.27e-05	9.64e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PNP—osteoporosis	2.26e-05	9.61e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ATIC—osteoporosis	2.26e-05	9.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6R—osteoporosis	2.21e-05	9.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6R—osteoporosis	2.18e-05	9.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IRS1—osteoporosis	2.17e-05	9.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADCY5—osteoporosis	2.13e-05	9.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SPP1—osteoporosis	2.06e-05	8.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—osteoporosis	2.04e-05	8.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6R—osteoporosis	2.04e-05	8.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADCY5—osteoporosis	1.99e-05	8.46e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.98e-05	8.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SPP1—osteoporosis	1.93e-05	8.18e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA2—osteoporosis	1.92e-05	8.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—OXCT1—osteoporosis	1.92e-05	8.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—osteoporosis	1.91e-05	8.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MGLL—osteoporosis	1.87e-05	7.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IRS2—osteoporosis	1.86e-05	7.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ENO1—osteoporosis	1.83e-05	7.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LEP—osteoporosis	1.82e-05	7.74e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSMA5—osteoporosis	1.81e-05	7.68e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSMA2—osteoporosis	1.81e-05	7.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—osteoporosis	1.81e-05	7.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1B—osteoporosis	1.8e-05	7.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IRS2—osteoporosis	1.74e-05	7.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ESR1—osteoporosis	1.74e-05	7.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LEP—osteoporosis	1.7e-05	7.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—osteoporosis	1.69e-05	7.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—osteoporosis	1.68e-05	7.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—osteoporosis	1.63e-05	6.91e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IRS1—osteoporosis	1.62e-05	6.9e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH2—osteoporosis	1.59e-05	6.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—POMC—osteoporosis	1.56e-05	6.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6R—osteoporosis	1.53e-05	6.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IRS1—osteoporosis	1.52e-05	6.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—osteoporosis	1.5e-05	6.39e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.5e-05	6.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP19A1—osteoporosis	1.47e-05	6.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—POMC—osteoporosis	1.46e-05	6.22e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ACP5—osteoporosis	1.46e-05	6.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6R—osteoporosis	1.43e-05	6.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—osteoporosis	1.41e-05	5.98e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TPI1—osteoporosis	1.35e-05	5.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—osteoporosis	1.29e-05	5.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—osteoporosis	1.29e-05	5.47e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—P4HB—osteoporosis	1.27e-05	5.41e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GAPDH—osteoporosis	1.25e-05	5.31e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RAP1A—osteoporosis	1.22e-05	5.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—osteoporosis	1.21e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—osteoporosis	1.21e-05	5.12e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ADCY5—osteoporosis	1.2e-05	5.09e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPX1—osteoporosis	1.19e-05	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—osteoporosis	1.15e-05	4.89e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—osteoporosis	1.1e-05	4.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—osteoporosis	1.08e-05	4.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—osteoporosis	1.05e-05	4.47e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO1—osteoporosis	9.84e-06	4.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—osteoporosis	9.84e-06	4.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—osteoporosis	9.71e-06	4.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSMA2—osteoporosis	9.7e-06	4.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSMA5—osteoporosis	9.7e-06	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—osteoporosis	9.08e-06	3.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—osteoporosis	9.04e-06	3.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—osteoporosis	9.02e-06	3.83e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—POMC—osteoporosis	8.81e-06	3.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—osteoporosis	8.46e-06	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—osteoporosis	8.44e-06	3.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	7.87e-06	3.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—osteoporosis	6.8e-06	2.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADCY5—osteoporosis	6.43e-06	2.73e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPX1—osteoporosis	6.41e-06	2.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—osteoporosis	6.36e-06	2.7e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—osteoporosis	5.91e-06	2.51e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—POMC—osteoporosis	4.73e-06	2.01e-05	CbGpPWpGaD
